Enzymatic removal of mannose moieties can increase the immune response to HIV-1 gp120 in vivo.
about
A Blueprint for HIV Vaccine DiscoveryGlycan clustering stabilizes the mannose patch of HIV-1 and preserves vulnerability to broadly neutralizing antibodiesHIV-1 Glycan Density Drives the Persistence of the Mannose Patch within an Infected Individual.Robust IgG responses to nanograms of antigen using a biomimetic lipid-coated particle vaccine.IgG subclass profiles in infected HIV type 1 controllers and chronic progressors and in uninfected recipients of Env vaccines.Design of a non-glycosylated outer domain-derived HIV-1 gp120 immunogen that binds to CD4 and induces neutralizing antibodies.Expression-system-dependent modulation of HIV-1 envelope glycoprotein antigenicity and immunogenicityPartial enzymatic deglycosylation preserves the structure of cleaved recombinant HIV-1 envelope glycoprotein trimers.Clinical adjuvant combinations stimulate potent B-cell responses in vitro by activating dermal dendritic cellsAn HIV-1 envelope glycoprotein trimer with an embedded IL-21 domain activates human B cellsComparative Immunogenicity of Evolved V1V2-Deleted HIV-1 Envelope Glycoprotein TrimersHow can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development?The function and affinity maturation of HIV-1 gp120-specific monoclonal antibodies derived from colostral B cellsOccluding the mannose moieties on human immunodeficiency virus type 1 gp120 with griffithsin improves the antibody responses to both proteins in mice.Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses.Effects of adjuvants on IgG subclasses elicited by virus-like particles.Glycan-dependent immunogenicity of recombinant soluble trimeric hemagglutinin.HIV-1 N-glycan composition governs a balance between dendritic cell-mediated viral transmission and antigen presentation.Altered Glycosylation Patterns Increase Immunogenicity of a Subunit Hepatitis C Virus Vaccine, Inducing Neutralizing Antibodies Which Confer Protection in Mice.Modulation of nonneutralizing HIV-1 gp41 responses by an MHC-restricted TH epitope overlapping those of membrane proximal external region broadly neutralizing antibodies.The multiple facets of HIV attachment to dendritic cell lectins.HIV-1 gp120 impairs the induction of B cell responses by TLR9-activated plasmacytoid dendritic cells.A mechanistic overview of dendritic cell-mediated HIV-1 trans infection: the story so far.Plasticity and Epitope Exposure of the HIV-1 Envelope Trimer.Enhancing the Quality of Antibodies to HIV-1 Envelope by GagPol-Specific Th Cells.Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralizationLack of complex N-glycans on HIV-1 envelope glycoproteins preserves protein conformation and entry function.Human plasmacytoid dendritic cells efficiently capture HIV-1 envelope glycoproteins via CD4 for antigen presentation.T-Cell Signaling in HIV-1 Infection.Differential immunogenicity and allergenicity of native and recombinant human lactoferrins: role of glycosylation.
P2860
Q26829865-81EB1DE0-C57E-49AF-8BE8-EE5BD26C9275Q28263932-9BC7FBC2-0DA7-4717-B0F7-B298FF62BAEBQ30393763-24F66D93-01F3-4110-AC6D-0C87594E899BQ30405708-1D2BD18E-ADBA-4AC5-B171-7D4AF3537C7DQ33827771-EEAA29A5-E728-4E44-9A20-18A5615DDF47Q34094476-268BC929-C3DA-4933-83EC-9D8F9CA5BBD9Q34175370-FDBA3E0B-8C4B-4276-A9B9-265F140D3635Q34285680-96F00D8F-AD5F-4C6B-AE68-52816A7C4414Q34735203-2FD8C06E-0F49-4DC6-9039-8B85339B8A93Q34796885-FC43EDFB-13B3-4D69-B79F-34EA35F9B4B6Q34807480-563BCAD1-BCC4-4ABB-94C0-D77DA9E47CEFQ35653703-D9DA7DEE-1FF0-4274-A4CB-6D15C07970C6Q35737800-F543E974-3634-4DC8-8719-0A688F9B0460Q35746244-DB337F31-7315-4C82-AAE4-E41969F5B152Q35826171-B4038405-17C5-4C3A-A4D8-DD3711C9E493Q35848642-D12D54AA-47C1-42F4-B515-90E8302BBEB3Q36363190-A9558928-5B03-435A-92AB-B10B1D485E0DQ36664069-07E4E6A1-3AC7-4334-A047-F1B9E0E628E0Q37415463-047FB565-EFF0-4072-A827-07123E02E534Q37607358-83CED59B-E7F5-43E9-BBA0-060702DF95A1Q37790420-179CDA59-B8B7-4C04-8BCD-2AD6BAA78DFDQ38320481-C47A0212-AE1C-4F8B-A0DE-FBBBE4D7B483Q38554932-48754FDF-2032-4F7B-922D-DFDEBFB65BFFQ38725480-DDE4E962-A111-4EF1-9B34-DC3C84B22B27Q38827936-794B8C18-A5EF-4C4F-8A18-7E78F5808FE3Q39723388-0A8B2E82-C34E-41A2-B1A0-A0CE56E8AC39Q39725329-17F38B0E-B47D-4DE4-8B2D-615B36E6CBA8Q41829933-2E9E7C80-D9E6-4A0B-B3F2-6495E9BDEFFEQ42273481-3E014A39-9789-42B0-9088-137C11D28DDEQ54002718-818CB16B-870D-4AF2-9181-E23C8286B4A3
P2860
Enzymatic removal of mannose moieties can increase the immune response to HIV-1 gp120 in vivo.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 02 May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Enzymatic removal of mannose m ...... sponse to HIV-1 gp120 in vivo.
@en
Enzymatic removal of mannose m ...... sponse to HIV-1 gp120 in vivo.
@nl
type
label
Enzymatic removal of mannose m ...... sponse to HIV-1 gp120 in vivo.
@en
Enzymatic removal of mannose m ...... sponse to HIV-1 gp120 in vivo.
@nl
prefLabel
Enzymatic removal of mannose m ...... sponse to HIV-1 gp120 in vivo.
@en
Enzymatic removal of mannose m ...... sponse to HIV-1 gp120 in vivo.
@nl
P2093
P2860
P1433
P1476
Enzymatic removal of mannose m ...... sponse to HIV-1 gp120 in vivo.
@en
P2093
Elizabeth Michael
John P Moore
Kaustuv Banerjee
Per Johan Klasse
Robert J Durso
Rogier W Sanders
Sofija Andjelic
Thomas J Ketas
William C Olson
P2860
P304
P356
10.1016/J.VIROL.2009.04.001
P407
P577
2009-05-02T00:00:00Z